Treatment of congestion in congestive heart failure: Ultrafiltration is the only rational initial Treatment of volume overload in decompensated heart failure

Circulation: Heart Failure

Volumn 2, Issue 5, 2009, Pages 499-504

  Bart, Bradley A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Diuretics; Edema; Heart failure; Sodium; Ultrafiltration

Indexed keywords

DIURETIC AGENT; FUROSEMIDE; ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; MORPHINE; NITRIC ACID DERIVATIVE; SODIUM; TOLVAPTAN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURETIC THERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; EVIDENCE BASED MEDICINE; EXTRACELLULAR FLUID; EXTRACELLULAR SPACE; GLOMERULUS FILTRATION RATE; HEARING LOSS; HEART FAILURE; HUMAN; HYPERVOLEMIA; HYPOXEMIA; INTERSTITIAL NEPHRITIS; LUNG EDEMA; NOTE; OSTEOLYSIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SODIUM INTAKE; SODIUM RETENTION; SODIUM URINE LEVEL; TREATMENT INDICATION; ULTRAFILTRATION; WATER RETENTION; ARTICLE; BLOOD; METABOLISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; EXTRACELLULAR FLUID; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; SODIUM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; ULTRAFILTRATION;

EID: 70350468576     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.863381     Document Type: Note

References (48)

1. Peters J. The role of sodium in the production of edema. N Engl J Med. 1948;239:353-362.
2. Gheorghiade M, Filippatos G, De LL, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119:S3-S10.
3. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-683.
4. Lahav M, Regev A, Ra'anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992;102:725-731.
5. Ali SS, Olinger CC, Sobotka PA, Dahle TG, Bunte MC, Blake D, Boyle AJ. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail. 2009;15:1-4.
6. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
7. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol. 2006;47:1-8.
8. Eknoyan G. A history of diuretics. In: Seldin D, Giebisch G, eds. Diurectic Agents: Clinical Physiology and Pharmacology. San Diego, CA: Academic Press; 1997:3-28.
9. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356:1966-1978.
10. Blaustein MP, Zhang J, Chen L, Hamilton BP. How does salt retention raise blood pressure? Am J Physiol Regul Integr Comp Physiol. 2006;290:R514-R523.
11. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation. 2000;101:856-861.
12. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594-1598.
13. Davis KL, Laine GA, Geissler HJ, Mehlhorn U, Brennan M, Allen SJ. Effects of myocardial edema on the development of myocardial interstitial fibrosis. Microcirculation. 2000;7:269-280.
14. Rubboli A, Sobotka PA, Euler DE. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. Am J Physiol. 1994;267:H1054-H1061.
15. Blake WD, Wegria R. Effect of increased renal venous pressure on renal function. Am J Physiol. 1949;157:1-13.
16. Damman K, van DV, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-588.
17. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
18. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216.
19. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
20. Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J. 2008;155:200-207.
21. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, Hennen J. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99-104.
22. Ko DT, Alter DA, Austin PC, You JJ, Lee DS, Qiu F, Stukel TA, Tu JV. Life expectancy after an index hospitalization for patients with heart failure: a population-based study. Am Heart J. 2008;155:324-331.
23. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387-395.
24. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840-847.
25. HFSA 2006 Comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1-e122.
26. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389-393.
27. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431-1439.
28. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708.
29. Hasselblad V, Gattis SW, Shah MR, Lokhnygina Y, O'connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064-1069.
30. Neuberg GW, Miller AB, O'connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-38.
31. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
32. Silverstein ME, Ford CA, Lysaght MJ, Henderson LW. Treatment of severe fluid overload by ultrafiltration. N Engl J Med. 1974;291:747-751.
33. Agostoni P, Marenzi G, Lauri G, Perego G, Schianni M, Sganzerla P, Guazzi MD. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96:191-199.
34. Agostoni PG, Marenzi GC, Pepi M, Doria E, Salvioni A, Perego G, Lauri G, Giraldi F, Grazi S, Guazzi MD. Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol. 1993;21:424-431.
35. Agostoni PG, Marenzi GC, Sganzerla P, Assanelli E, Guazzi M, Perego GB, Lauri G, Doria E, Pepi M, Guazzi MD. Lung-heart interaction as a substrate for the improvement in exercise capacity after body fluid volume depletion in moderate congestive heart failure. Am J Cardiol. 1995;76:793-798.
36. Pepi M, Marenzi GC, Agostoni PG, Doria E, Barbier P, Muratori M, Celeste F, Guazzi MD. Sustained cardiac diastolic changes elicited by ultrafiltration in patients with moderate congestive heart failure: pathophysiological correlates. Br Heart J. 1993;70:135-140.
37. Fauchald P, Forfang K, Amlie J. An evaluation of ultrafiltration as treatment of therapy-resistant cardiac edema. Acta Med Scand. 1986;219:47-52.
38. Inoue T, Sakai Y, Morooka S, Takayanagi K, Hayashi T, Takabatake Y. Hemofiltration as treatment for patients with refractory heart failure. Clin Cardiol. 1992;15:514-518.
39. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38:963-968.
40. Rimondini A, Cipolla C, Della Bella P, Grazi S, Sisillo E, Susini G, Guazzi MD. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med. 1987;83:43-48.
41. Agostoni PG, Guazzi M, Bussotti M, Grazi M, Palermo P, Marenzi G. Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. J Am Coll Cardiol. 2000;36:1600-1604.
42. Canaud B, Cristol JP, Klouche K, Beraud JJ, Du CG, Ferriere M, Grolleau R, Mion C. Slow continuous ultrafiltration: a means of unmasking myocardial functional reserve in end-stage cardiac disease. Contrib Nephrol. 1991;93:79-85.
43. Cipolla CM, Grazi S, Rimondini A, Susini G, Guazzi M, Della BP, Guazzi MD. Changes in circulating norepinephrine with hemofiltration in advanced congestive heart failure. Am J Cardiol. 1990;66:987-994.
44. Forslund T, Riddervold F, Fauchald P, Torvik D, Fyhrquist F, Simonsen S. Hormonal changes in patients with severe chronic congestive heart failure treated by ultrafiltration. Nephrol Dial Transplant. 1992;7:306-310.
45. Guazzi MD, Agostoni P, Perego B, Lauri G, Salvioni A, Giraldi F, Matturri M, Guazzi M, Marenzi G. Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J. 1994;72:534-539.
46. Marenzi G, Grazi S, Giraldi F, Lauri G, Perego G, Guazzi M, Salvioni A, Guazzi MD. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med. 1993;94:49-56.
47. Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, Mackedanz S, Sobotka PA, Schollmeyer M, Goldsmith SR. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043-2046.
48. Bart BA, Insel J, Goldstein MM, Guglin ME, Hibbler KD, Schollmeyer MP, Sobotka P, Costanzo MR. The improved outcomes following Ultrafiltration versus intravenous diuretics in UNLOAD are not solely due to increased weight loss in the Ultrafiltration group. J Card Fail. 2007;13 (suppl 2) :S188.